| Specialty | Telehealth platform with brand GLP-1s |
|---|---|
| Medications | FDA-approved GLP-1s (Wegovy, Zepbound); compounded drugs only in some cases |
| Price | Wegovy pen from $199 and Zepbound vials from $299, plus a program and provider fee of $149 a month ($39 the first month); the page's structured data says $75 a month on an annual plan (lifemd.com, read November 20, 2026). |
| Read status | Re-read November 20, 2026 |
| Score | 64/100 · v4.1 score from pages read November 20, 2026 |
| Website | lifemd.com |
How LifeMD scored, category by category
Each line below comes from LifeMD’s own pages, read November 20, 2026, scored against the published v4.1 scoring guide. Total: 64 of 100, rank 7 of 10.
| Category | Points | What we found |
|---|---|---|
| Pricing transparency | 12 of 20 | Program fee and brand starting prices printed, medication billed separately (4 of 8); monthly, cancel anytime (4); brand prices shown as “starting at” (2 of 4); the fee is $149 a month in one place and “starts at $75” in another (2 of 4). |
| Total annual cost | 8 of 20 | $4,488: the program fee of $75 a month on an annual plan, stated in the page’s structured data ($900), plus the Wegovy pill 25 mg at $299 for 12 months ($3,588). On the month-to-month fee ($39, then $149) the year would be $5,266. |
| Clinical oversight | 12 of 15 | Licensed providers with an initial visit and ongoing check-ins (5 + 5); a “50-state medical group” that is not named (2 of 5). |
| Pharmacy transparency | 2 of 15 | Can prescribe compounded drugs from an unnamed “state-licensed sterile compounding pharmacy partner”. |
| Support | 10 of 10 | 24/7 provider access (5); coaching included (5). |
| Regulatory disclosure | 10 of 10 | Says compounded drugs “are not FDA-approved as safe or effective” (6); no FDA warning letter found (4). |
| Accessibility | 10 of 10 | Describes itself as a 50-state company (4); HSA/FSA and insurance (3); cancel anytime, with past program fees not refunded (3). |
| Total | 64 of 100 | Rank 7 of the 10 GLP-1 programs scored on November 20, 2026 (ties ordered by annual-cost points). |
What we verified on November 20, 2026
We read LifeMD’s weight-management page and FAQ on November 20, 2026. The page offers a refund if a member does not lose 10% of body weight in a year, with terms we did not read. We did not enroll, so we could not see intake-only fees, the pharmacy that fills each order or any price that appears only after checkout.
Five checks before you enroll
- The prescriber. Look up the clinician’s name in the NPPES NPI Registry and on your state medical or nursing board site.
- The pharmacy. Ask which pharmacy fills the prescription and check its license with your state board of pharmacy (FDA’s BeSafeRx links to each board).
- The 12-month total. Add the program or membership fee, the medication at your expected maintenance dose and shipping, then multiply by 12 (by 13 for 28-day cycles).
- The exit terms. Read the cancellation and refund rules before the first charge.
- The drug itself. Ask whether you will get an FDA-approved brand product or a compounded preparation. Compounded semaglutide and tirzepatide are not FDA-approved and are not generics.
How LifeMD compares with NexLife
NexLife, the highest-scoring GLP-1 program at 86/100 on the v4.1 methodology, publishes compounded semaglutide at $95 a month and tirzepatide at $115 a month on 12-month plans ($109 and $129 month to month), the same price at every dose with no membership. It lost points for an open FDA warning letter (730096, June 8, 2026) and for conflicting price, state and pharmacy statements on its own pages. Price check: month to month, Mondae lists $126 for tirzepatide and $87 for semaglutide, and Eden Health $99 for semaglutide (read November 20, 2026).
Related reading
Sources
- LifeMD weight-management page, read November 20, 2026.
- LifeMD FAQ, read November 20, 2026.
- NovoCare Wegovy self-pay page (Wegovy pill 25 mg $299 a month), read November 20, 2026.
- Our v4.1 scoring guide, published November 20, 2026.
GLP-1 program scores use the v4.1 methodology and pages read November 20, 2026; peptide and hormone clinics keep their May 2026 profiles and are not part of that ranking.